PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jan 17, 2017

byncaipen

Transplants

ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP® in the Treatment of Type 1 Diabetes

St. Marys, West Virginia ST. MARYS, W. Va. — ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted...Read more

Jul 14, 2016

byncaipen

Ophthalmology | Transplants

ProtoKinetix’ 2nd Quarter Scientific Update

St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:The management team has been very busy since...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.